Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bolt Biotherapeutics Inc (NQ: BOLT )

0.7390 +0.0090 (+1.23%)
Streaming Delayed Price Updated: 1:52 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 63,694
Open 0.7500
Bid (Size) 0.7206 (1)
Ask (Size) 0.7299 (1)
Prev. Close 0.7300
Today's Range 0.7205 - 0.7502
52wk Range 0.7100 - 1.560
Shares Outstanding 8,709,974
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt
From Faruqi & Faruqi LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FutureFuel, SeaStar, and Bolt and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
-36.29%
-36.29%
1 Month
-1.45%
-1.45%
3 Month
-33.42%
-33.42%
6 Month
-35.74%
-35.74%
1 Year
-45.26%
-45.26%

More News

Read More
BOLT Stockholders with Large Losses Should Contact Robbins LLP for Information About the Bolt Biotherapeutics, Inc. Class Action Lawsuit
From Robbins LLP
Via Business Wire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SeaStar and Bolt and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
BOLT Class Action Alert: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Class Action Against Bolt Biotherapeutics, Inc.
From Robbins LLP
Via GlobeNewswire
BOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
BOLT ALERT: Bragar Eagel & Squire, P.C. is Investigating Bolt Biotherapeutics, Inc. on Behalf of Bolt Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT
From The Rosen Law Firm PA
Via GlobeNewswire
Bolt Biotherapeutics, Inc. Stockholder Notice: Robbins LLP Reminds Investors of the BOLT Class Action
From Robbins LLP
Via Business Wire
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT
From The Rosen Law Firm PA
Via GlobeNewswire
Shareholder Alert: Robbins LLP Informs Stockholders of the Class Action Filed Against Bolt Biotherapeutics, Inc. (BOLT)
From Robbins LLP
Via GlobeNewswire
BOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ROSEN, A TOP RANKED LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT
From The Rosen Law Firm, P.A.
Via Business Wire
The Analyst Anxiety Index: 3 Stocks to Avoid as Uncertainty Grows
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
This Accenture Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Today
Via Benzinga
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.